Subject(s)
Anti-Infective Agents/therapeutic use , Gastritis/drug therapy , Helicobacter Infections/drug therapy , Hydroxybenzoates/therapeutic use , Nitrofurans/therapeutic use , Peptic Ulcer/drug therapy , 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Adult , Anti-Infective Agents/administration & dosage , Chronic Disease , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Drug Therapy, Combination , Female , Gastritis/microbiology , Helicobacter Infections/microbiology , Humans , Hydroxybenzoates/administration & dosage , Male , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Nitrofurans/administration & dosage , Pantoprazole , Peptic Ulcer/microbiology , Treatment OutcomeABSTRACT
Gluten-sensitive enteropathy (Celiac Disease)--is an autoimmune inflammatory disease, with hyper Regenerative atrophy of the mucous membrane of the small intestine, that is precipitated by the ingestion of gluten, a component of wheat rye, barley, protein. Exclusion of dietary gluten results in healing of the mucosa of the small intestine. The main method of treatment and prevention of complications of celiac disease is strict lifelong adherence to gluten-free diet (AGD), which reduces the quality of life of patients. The labeling of all foods and greater variety of gluten-free products, reducing their cost, psychological support doctors and nutritionists will improve their quality of life.
Subject(s)
Autoimmune Diseases/economics , Celiac Disease/economics , Diet, Gluten-Free/economics , Diet, Gluten-Free/methods , Food Labeling , Glutens , Autoimmune Diseases/epidemiology , Autoimmune Diseases/therapy , Celiac Disease/epidemiology , Celiac Disease/therapy , Humans , Russia/epidemiologyABSTRACT
Treatment of inflammatory diseases of the upper digestive tract, associated with Helicobacter pylori has recently greatly complicated by the presence of significant number of resistant strains of this microorganism to traditionally used drugs for eradication therapy. Average resistance to metronidazole and clarithromycin in Russia is about 30 and 25% respectively. The article presents the experience of treating patients with metronidazole resistant strains of H. pylori with using triple therapy, which included a drug used nitrofurans--nifuroxazide in suspension, proton pump inhibitors and clarithromycin.
